NextCell Pharma AB (STO:NXTCL)
Sweden · Delayed Price · Currency is SEK 0.9940
-0.0080 (-0.80%)
Aug 13, 2026, 4:42 PM CET
NextCell Pharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Aug '25 Aug 31, 2025 | Dec '24 Dec 31, 2024 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 |
Cash & Equivalents | 32.33 | 26.03 | 38.72 | 32.7 | 46.79 | 50.03 |
Cash & Short-Term Investments | 32.33 | 26.03 | 38.72 | 32.7 | 46.79 | 50.03 |
Cash Growth | -31.09% | -32.77% | 18.43% | -30.12% | -6.47% | -48.49% |
Accounts Receivable | 3.7 | 3.06 | 3 | 2.1 | 1.67 | 2.35 |
Other Receivables | 11.25 | 2.4 | 1.98 | 2.14 | 1.45 | 1.24 |
Total Trade Receivables | 14.95 | 5.47 | 4.98 | 4.23 | 3.12 | 3.58 |
Inventory | 0.33 | 0.33 | 0.55 | 0.55 | 0.55 | 0.79 |
Other Current Assets | - | 9.57 | 10.15 | 8.67 | 10.22 | 12.87 |
Total Current Assets | 47.61 | 41.4 | 54.4 | 46.14 | 60.67 | 67.27 |
Net Property, Plant & Equipment | 13.96 | 14.27 | 14.33 | 11.91 | 12.66 | 13.55 |
Long-Term Investments | - | 7.2 | 6.87 | 6.87 | 6.87 | 6.87 |
Other Long-Term Assets | - | 1.05 | 1.14 | 1.09 | 1.08 | 1.13 |
Total Assets | 69.82 | 63.92 | 76.73 | 66.02 | 81.29 | 88.83 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Aug '25 Aug 31, 2025 | Dec '24 Dec 31, 2024 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 |
Accounts Payable | 5.01 | 3.34 | 2.69 | 2.22 | 6.16 | 0.89 |
Accrued Expenses | - | 3.38 | 2.25 | 1.73 | 2.74 | 7.84 |
Other Current Liabilities | 4.71 | 1.31 | 0.49 | 1.63 | 0.98 | 1.35 |
Total Current Liabilities | 9.72 | 8.03 | 5.43 | 5.58 | 9.87 | 10.08 |
Other Long-Term Liabilities | 5.11 | 5.29 | 4.92 | 4.42 | 3.82 | 3.02 |
Total Long-Term Liabilities | 5.11 | 5.29 | 4.92 | 4.42 | 3.82 | 3.02 |
Total Liabilities | 14.83 | 13.32 | 10.34 | 10 | 13.69 | 13.1 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Aug '25 Aug 31, 2025 | Dec '24 Dec 31, 2024 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 |
Common Stock | 25.91 | 22.84 | 22.84 | 14.98 | 14.98 | 7.05 |
Additional Paid-in Capital | 260.11 | 248.41 | 248.41 | 222.33 | 222.33 | 196.43 |
Retained Earnings | -231.03 | -220.64 | -204.85 | -181.29 | -169.71 | -127.75 |
Shareholders' Equity | 54.99 | 50.6 | 66.39 | 56.02 | 67.6 | 75.73 |
Total Liabilities & Equity | 69.82 | 63.92 | 76.73 | 66.02 | 81.29 | 88.83 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Aug '25 Aug 31, 2025 | Dec '24 Dec 31, 2024 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 |
Net Cash (Debt) | 32.33 | 26.03 | 38.72 | 32.7 | 46.79 | 50.03 |
Net Cash Growth | -31.09% | -32.77% | 18.43% | -30.12% | -6.47% | -48.49% |
Net Cash Per Share | 0.30 | 0.30 | 0.51 | 0.80 | 1.15 | 1.46 |
Book Value | 54.99 | 50.6 | 66.39 | 56.02 | 67.6 | 75.73 |
Book Value Per Share | 0.52 | 0.59 | 0.87 | 1.37 | 1.66 | 2.20 |
Tangible Book Value | 54.99 | 50.6 | 66.39 | 56.02 | 67.6 | 75.73 |
Tangible Book Value Per Share | 0.52 | 0.59 | 0.87 | 1.37 | 1.66 | 2.20 |